Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16267699 | 1.00 | CTSS (0.52) | CTSSCTSKPOLBATMNLRP3 | |
| SCHEMBL9849180 | 1.00 | CTSS (0.52) | CTSSCTSKPOLBATMNLRP3 | |
| SCHEMBL32677103 | 0.90 | CTSS (0.49) | CTSSCTSKPOLBATMNLRP3 | |
| SCHEMBL32676842 | 0.90 | CTSS (0.49) | CTSSCTSKPOLBATMNLRP3 | |
| SCHEMBL32677127 | 0.90 | CTSS (0.49) | CTSSCTSKPOLBATMNLRP3 | |
| SCHEMBL2153385 | 0.88 | TACR1 (0.46) | CTSSCTSKPOLBATMNLRP3 | |
| SCHEMBL9849060 | 0.88 | CTSS (0.55) | CTSSCTSKALDH1A1KMT2A | |
| SCHEMBL16267725 | 0.88 | CTSS (0.55) | CTSSCTSKALDH1A1KMT2A | |
| SCHEMBL30082804 | 0.88 | TACR1 (0.46) | CTSSCTSKPOLBATMNLRP3 | |
| SCHEMBL2780646 | 0.88 | CTSS (0.55) | CTSSCTSKALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503442-B2 | Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1receptor positive allosteric modulators | ELI LILLY AND COMPANY (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| CN-111971282-B | Pyrazolotetrahydroisoquinoline derivatives as dopamine D1 receptor positive modulators | 伊莱利利公司 | 2024-03-19 | — | — | CN | disclosed |
| EP-4200280-B1 | PHENYL-3,4-DIHYDROISOQUINOLIN-2(1H)-YL-ETHAN-1-ONE DERIVATIVES AS DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | LILLY CO ELI (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20230382869-A1 | Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1receptor positive allosteric modulators | ELI LILLY AND COMPANY | 2023-11-30 | — | — | US | disclosed |
| CN-116601146-A | Phenyl-3, 4-dihydroisoquinolin-2 (1H) -yl-ethan-1-one derivatives as positive allosteric modulators of dopamine D1 receptor | 伊莱利利公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-4200280-A1 | PHENYL-3,4-DIHYDROISOQUINOLIN-2(1H)-YL-ETHAN-1-ONE DERIVATIVES AS DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | ELI LILLY AND COMPANY (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-3781560-B1 | PYRAZO-TETRAHYDROISOQUINOLINE DERIVATIVES AS DOPAMINE D1 RECEPTOR POSITIVE MODULATORS | LILLY CO ELI (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2022076418-A1 | PHENYL-3,4-DIHYDROISOQUINOLIN-2(1H)-YL-ETHAN-1-ONE DERIVATIVES AS DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | ELI LILLY AND COMPANY (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-3781560-A1 | PYRAZO-TETRAHYDROISOQUINOLINE DERIVATIVES AS DOPAMINE D1 RECEPTOR POSITIVE MODULATORS | Eli Lilly and Company (US) | 2021-02-24 | — | — | EP | disclosed |
| CN-111971282-A | Pyrazolotetrahydroisoquinoline derivatives as positive modulators of dopamine D1 receptor | 伊莱利利公司 | 2020-11-20 | — | — | CN | disclosed |
| US-10611751-B2 | Dopamine D1 receptor positive allosteric modulators | ELI LILLY AND COMPANY (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190322639-A1 | DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | ELI LILLY AND COMPANY | 2019-10-24 | — | — | US | disclosed |
| WO-2019204418-A1 | PYRAZO-TETRAHYDROISOQUINOLINE DERIVATIVES AS DOPAMINE D1 RECEPTOR POSITIVE MODULATORS | ELI LILLY AND COMPANY (US) | 2019-10-24 | — | — | WO | disclosed |
| EP-0421436-A2 | Substituted carboxytetrahydroisoquinolines and derivatives thereof having pharmaceutical activity | WARNER-LAMBERT COMPANY (US) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382869-A1 | Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1receptor positive allosteric modulators | HTR1D, ADRA1D, HTR1A | CTSS 2106/4885CTSK 3844/4885POLB 4263/4885 |
| US-12503442-B2 | Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1receptor positive allosteric modulators | HTR1D, ADRA1D, HTR1A | CTSS 2106/4885CTSK 3844/4885POLB 4263/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | CTSS 2619/4885CTSK 1860/4885POLB 4132/4885 |
| US-10611751-B2 | Dopamine D1 receptor positive allosteric modulators | ADRA1D, DRD2, HTR1D | CTSS 2638/4885CTSK 3360/4885POLB 4049/4885 |
| US-20190322639-A1 | DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | ADRA1D, DRD2, HTR1D | CTSS 2638/4885CTSK 3360/4885POLB 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.